Added to YB: 2026-05-11
Pitch date: 2026-05-07
STVN [neutral]
Stevanato Group S.p.A.
-1.35%
current return
Author Info
Best Anchor Stocks shares deep research on companies with long-term potential aThe Bear Cavend lower-than-average volatility. Sign up for the newsletter.
Company Info
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific.
Market Cap
$4.4B
Pitch Price
$18.48
Price Target
N/A
Dividend
N/A
EV/EBITDA
16.21
P/E
31.70
EV/Sales
3.95
Sector
Life Sciences Tools and Services
Category
growth
The consequences of vertigo - Stevanato Group S.p.A.
STVN (earnings): Q1 rev +10% YoY, BDS +16% accelerated 300bps sequentially; strong HVS +22% offset by weak engineering -31%. BDS gross margin dropped 300bps on depreciation, FX, tariffs & lumpy pilot project. GLP-1 now 21-22% of rev (+50% in '25), non-GLP +6%. Mgmt requalifying RTU vial line to cartridge (demand>supply), bulk capacity online late '26/early '27. Guided 9% organic growth '26 implies 7% non-GLP growth. Stock -5% despite good fundamentals.
Read full article (5 min)